Repligen Corporation (RGEN)
Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth
Repligen Corp RGEN released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents.
Repligen (RGEN) Q3 Earnings and Revenues Beat Estimates
Repligen (RGEN) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.23 per share a year ago.
Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects
Repligen Corporation is a bioprocessing technology company focusing on process intensification, purification, and fluid management, with strategic acquisitions to enhance its capabilities. Though integration risks remain, RGEN's recent acquisition of Tantti Laboratory aims to bolster its chromatography and biomolecule purification capacities. The potential acquisition of Maravai LifeSciences could impact RGEN's future growth, but past failed attempts and divestment plans add uncertainty.
Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Q3 Release
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exclusive: Repligen in bid for reagent vendor Maravai, sources say
Repligen , a provider of drug manufacturing equipment, has approached Maravai LifeSciences Holdings , a vaccine capping reagent vendor that has a market value of $2.2 billion, with an acquisition offer, people familiar with the matter said on Friday.
Here's Why Shares in This Hot Healthcare Stock Surged This Week
A far larger peer backs up Repligen's market commentary. Bioprocessing customers are working through inventory, and orders growth is bouncing back.
These Analysts Revise Their Forecasts On Repligen Following Q2 Results
Repligen Corporation RGEN reported in-line earnings for its second quarter on Tuesday.
Repligen's (RGEN) Q2 Earnings & Revenues Meet Estimates
Repligen's (RGEN) second-quarter earnings and revenues match estimates. The company narrows its revenue guidance for 2024.
Repligen Corporation (RGEN) Q2 2024 Earnings Call Transcript
Repligen Corporation [RGEN] Q2 2024 Earnings Conference Call July 30, 2024 8:30 AM ET Company Participants Tony Hunt - CEO Jason Garland - CFO Olivier Loeillot - President & CCO Sondra Newman - IR Conference Call Participants Rachel Vatnsdal - J.P. Morgan Dan Arias - Stifel Jacob Johnson - Stephens Inc. Puneet Souda - Leerink Partners Justin Bowers - Deutsche Bank Matt Larew - William Blair Conor McNamara - RBC Capital Markets Dan Leonard - UBS Paul Knight - KeyBanc Matt Hewitt - Craig-Hallum Capital Group Matt Stanton - Jefferies Tom DeBourcy - Nephron Research Subbu Nambi - Guggenheim Securities Operator Good day, ladies and gentlemen, and welcome to Repligen Corporation's Second Quarter of 2024 Earnings Conference Call.
Repligen Lowers Guidance On China Weakness, Analyst Expects
Tuesday, Repligen Corporation RGEN reported second-quarter sales of $154.1 million, almost in line with the consensus estimate of $154.12 million.
Repligen (RGEN) Q2 Earnings Meet Estimates
Repligen (RGEN) came out with quarterly earnings of $0.33 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.53 per share a year ago.
Analysts Estimate Repligen (RGEN) to Report a Decline in Earnings: What to Look Out for
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
